KD Logo

Stifel analysts downgrades a Hold rating for Cara Therapeutics Inc (CARA)

Cara Therapeutics Inc’s recent filing unveils that its PRESIDENT AND CEO Posner Christopher unloaded Company’s shares for reported $2952.0 on May 02 ’24. In the deal valued at $0.75 per share,3,936 shares were sold. As a result of this transaction, Posner Christopher now holds 176,585 shares worth roughly $51209.649999999994.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Terrillion Scott sold 2,753 shares, generating $2,285 in total proceeds. Upon selling the shares at $0.83, the SEC’Y; CHIEF COMPLIANCE & G.C. now owns 88,247 shares.

Before that, Goncalves Joana sold 2,753 shares. Cara Therapeutics Inc shares valued at $2,285 were divested by the CHIEF MEDICAL OFFICER at a price of $0.83 per share. As a result of the transaction, Goncalves Joana now holds 53,365 shares, worth roughly $15475.849999999999.

Stifel downgraded its Cara Therapeutics Inc [CARA] rating to a Hold from a a Buy in a research note published on June 13, 2024; the price target was decreased to $1 from $6. A number of analysts have revised their coverage, including Needham’s analysts, who decreased its forecast for the stock in mid June from “a Buy” to “a Hold”. H.C. Wainwright also remained covering CARA and has decreased its forecast on June 13, 2024 with a “Neutral” recommendation from previously “Buy” rating. Canaccord Genuity revised its rating on June 13, 2024. It rated CARA as “a Hold” which previously was an “a Buy”.

Price Performance Review of CARA

On Tuesday, Cara Therapeutics Inc [NASDAQ:CARA] saw its stock jump 0.14% to $0.29. Over the last five days, the stock has gained 8.52%. Cara Therapeutics Inc shares have fallen nearly -61.59% since the year began. Nevertheless, the stocks have fallen -89.31% over the past one year. While a 52-week high of $3.45 was reached on 03/04/24, a 52-week low of $0.24 was recorded on 06/20/24. SMA at 50 days reached $0.5724, while 200 days put it at $0.8586. A total of 0.63 million shares were traded, compared to the trading of 0.93 million shares in the previous session.

Levels Of Support And Resistance For CARA Stock

The 24-hour chart illustrates a support level at 0.2719, which if violated will result in even more drops to 0.2585. On the upside, there is a resistance level at 0.2989. A further resistance level may holdings at 0.3125. The Relative Strength Index (RSI) on the 14-day chart is 34.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0024, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 64.78%. Stochastics%K at 30.26% indicates the stock is a holding.

Most Popular